Blue Water Vaccines, a preclinical biotech developing vaccines for the flu and other infectious diseases, raised $20 million by offering 2.2 million shares at $9, within the range of $8 to $10.
Blue Water is focused on the research and development of transformational vaccines to prevent infectious diseases worldwide using its versatile vaccine platform, which can be utilized to develop singular or multi-targeted vaccines. Its pipeline includes novel vaccine candidates exclusively licensed from research institutions. The company's lead program, BWV-101, is licensed from the University of Oxford and is being developed as a transformational novel universal influenza vaccine.
Blue Water Vaccines plans to list on the Nasdaq under the symbol BWV. Boustead Securities acted as sole bookrunner on the deal.
